Therapeutics News and Research

RSS

NHS to produce unique stem cells that could revolutionize treatment for diabetic kidney disease

NHS Blood and Transplant will start producing stem cells for groundbreaking treatment aimed at combating one of the most serious health problems facing the NHS, diabetic kidney disease.

22 Oct 2015

UF Health researcher reveals how betel nut's psychoactive chemical works in the brain

For hundreds of millions of people around the world, chewing betel nut produces a cheap, quick high but also raises the risk of addiction and oral cancer. Now, new findings by a University of Florida Health researcher reveal how the nut's psychoactive chemical works in the brain and suggest that an addiction treatment may already exist.

22 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee has reviewed the initial safety data from all three patients in the first cohort and has recommended dose escalation to the second cohort.

20 Oct 2015

First patients receive doses of antisense drug for Huntington's disease

The first few patients have received doses of an experimental RNA-targeting drug for Huntington's disease, it was announced today.

20 Oct 2015

Ember Therapeutics reports initial results from BMP-7 Phase II trial in patients with moderate osteoarthritis of the knee

Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, announced today initial results from the Phase II(a) trial of local BMP-7 administration in patients with moderate osteoarthritis of the knee.

20 Oct 2015

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016.

19 Oct 2015

Immatics, UTHealth to partner on cellular manufacturing for adoptive cellular therapy clinical trials

Immatics US, Inc., a subsidiary of Immatics Biotechnologies GmbH, and The University of Texas Health Science Center at Houston will collaborate on cellular manufacturing for adoptive cellular therapy (ACT) clinical trials.

19 Oct 2015

UB study sheds light on the root causes of Huntington's disease

We've known for years that the Huntingtin protein (Htt) is responsible for Huntington's disease, a neurodegenerative disorder that diminishes a person's mental and physical abilities.

19 Oct 2015

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

Researchers at the Translational Genomics Research Institute joined an international team of scientists in discovering how a protein from malaria could some day help stop cancer.

19 Oct 2015

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.

19 Oct 2015

Aratana announces $40 million senior secured credit facility

Aratana Therapeutics, Inc., a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced a $40 million senior secured credit facility with Pacific Western Bank, as agent and lender, and Oxford Finance LLC, as lender. The facility refinances the $15 million loan facility previously provided to the Company by Pacific Western Bank (as successor-in-interest to Square 1 Bank).

16 Oct 2015

Set of genes identified in human genome essential for survival, proliferation of human cell lines

Using two complementary analytical approaches, scientists at Whitehead Institute and Broad Institute of MIT and Harvard have for the first time identified the universe of genes in the human genome essential for the survival and proliferation of human cell lines or cultured human cells.

16 Oct 2015

Study shows why cancer anemia therapy stimulates tumor growth

Scientists have shown why a drug widely used to treat chemotherapy-induced anemia in ovarian and breast cancer patients also may shorten survival times in some patients by inadvertently stimulating tumor growth.

16 Oct 2015

Genomic analysis confirms sexual transmission of Ebola virus in Liberia

A suspected case of sexual transmission of Ebola virus disease (EVD) in Liberia was confirmed using genomic analysis, thanks to in-country laboratory capabilities established by U.S. Army scientists in collaboration with the Liberian Institute for Biomedical Research (LIBR).

16 Oct 2015

Omeros launches OMIDRIAssure program to provide expanded patient access to Omidria

Omeros Corporation today announced that it has launched OMIDRIAssure, a comprehensive reimbursement services program to provide expanded access to Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% for cataract surgery patients and reimbursement assistance for physicians and facilities.

15 Oct 2015

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

Bio-molecules present in human breast milk can help resolve inflammation, combat infection

Human breast milk, which provides essential nutrients and antibodies to newborns, has long been known to play an important role in infant development and the immune system. In a new study published in Mucosal Immunology, researchers from Brigham and Women's Hospital report that human breast milk serves as a reservoir for bio-molecules that help to resolve inflammation and combat infection.

15 Oct 2015

LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, announced today that the LEADERS FREE clinical trial demonstrated superior safety and efficacy for BioFreedom compared with a bare-metal stent (BMS).

15 Oct 2015

First-in-human compassionate use cases with Edwards' FORMA transcatheter tricuspid repair system presented at TCT

Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that details on the 13 first-in-human compassionate use cases with its FORMA transcatheter tricuspid repair system were presented at the 27th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.

15 Oct 2015

Therapeutics News and Research

NHS to produce unique stem cells that could revolutionize treatment for diabetic kidney disease

UF Health researcher reveals how betel nut's psychoactive chemical works in the brain

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

First patients receive doses of antisense drug for Huntington's disease

Ember Therapeutics reports initial results from BMP-7 Phase II trial in patients with moderate osteoarthritis of the knee

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

Immatics, UTHealth to partner on cellular manufacturing for adoptive cellular therapy clinical trials

UB study sheds light on the root causes of Huntington's disease

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

Aratana announces $40 million senior secured credit facility

Set of genes identified in human genome essential for survival, proliferation of human cell lines

Study shows why cancer anemia therapy stimulates tumor growth

Genomic analysis confirms sexual transmission of Ebola virus in Liberia

Omeros launches OMIDRIAssure program to provide expanded patient access to Omidria

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

Bio-molecules present in human breast milk can help resolve inflammation, combat infection

LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

First-in-human compassionate use cases with Edwards' FORMA transcatheter tricuspid repair system presented at TCT

Next-generation therapeutics eBook eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News